Stokes Family Office’s Gilead Sciences GILD Stock Holding History

Stokes Family Office’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$318K	Sell	2,280 -453	-17%	-$63.4K	0.03%	229
2025 Q4	$335K	Buy	2,733 +604	+28%	+$73.4K	0.03%	238
2025 Q3	$236K	Buy	2,129 +47	+2%	+$5.34K	0.02%	240
2025 Q2	$231K	Buy	2,082 +5	+0.2%	+$532	0.02%	216
2025 Q1	$233K	Buy	+2,077	New	+$214K	0.03%	216
2023 Q3	–	Sell	-2,606	Closed	-$201K	–	349
2023 Q2	$201K	Buy	2,606 +143	+6%	+$11.4K	0.02%	301
2023 Q1	$204K	Sell	2,463 -217	-8%	-$18K	0.03%	277
2022 Q4	$230K	Buy	+2,680	New	+$212K	0.03%	246

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Stokes Family Office's GILD Position: Q1 2026 in Review

Stokes Family Office reduced its Gilead Sciences (GILD) stake by 17% in Q1 2026, selling an estimated $63.4K and leaving 2,280 shares worth $318K. The position accounts for 0.03% of the portfolio, ranked #229.

Stokes Family Office first reported a position in GILD in Q4 2022 and has held it in 8 quarters since. The position peaked at $335K in Q4 2025. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Stokes Family Office held 2,280 shares of Gilead Sciences worth $318K as of Q1 2026.
Stokes Family Office sold 453 Gilead Sciences shares in Q1 2026, an estimated $63.4K.
Gilead Sciences made up 0.03% of Stokes Family Office's portfolio in Q1 2026, its #229 holding.
Stokes Family Office first reported a position in Gilead Sciences in Q4 2022 and has held it in 8 quarters since.
Stokes Family Office's Gilead Sciences position peaked at $335K in Q4 2025.
2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Stokes Family Office's 13F filing for Q1 2026, filed 12 May 2026.